HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans

CD Spinner, C Boesecke, A Zink, H Jessen… - Infection, 2016 - Springer
Purpose Despite established HIV prevention strategies and broadly available diagnostic
strategies in developed western countries, rates of HIV new infections remain high …

Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program

Mind Exchange Working Group… - Clinical Infectious …, 2013 - academic.oup.com
Many practical clinical questions regarding the management of human immunodeficiency
virus (HIV)–associated neurocognitive disorder (HAND) remain unanswered. We sought to …

SARS-CoV-2-specific antibody detection in healthcare workers in Germany with direct contact to COVID-19 patients

J Korth, B Wilde, S Dolff, OE Anastasiou… - Journal of Clinical …, 2020 - Elsevier
Background The novel coronavirus SARS-CoV-2 is associated with a severe respiratory
manifestation, COVID-19, and presents a challenge for healthcare systems worldwide …

Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials

PE Sax, KM Erlandson, JE Lake… - Clinical Infectious …, 2020 - academic.oup.com
Background Initiation of antiretroviral therapy (ART) often leads to weight gain. While some
of this weight gain may be an appropriate return-to-health effect, excessive increases in …

Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART)

M Maschke, O Kastrup, S Esser, B Ross… - Journal of Neurology …, 2000 - jnnp.bmj.com
OBJECTIVE To determine the change of incidence and prevalence of neurological disorders
caused by the human immunodeficiency virus (HIV) and opportunistic infections in HIV …

Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and …

P Cahn, JS Madero, JR Arribas, A Antinori, R Ortiz… - The Lancet, 2019 - thelancet.com
Background Effective two-drug regimens could decrease long-term drug exposure and
toxicity with HIV-1 antiretroviral therapy (ART). We therefore aimed to evaluate the efficacy …

HIV-associated Kaposi's sarcoma

C Hoffmann, M Sabranski, S Esser - Oncology research and treatment, 2017 - karger.com
Kaposi's sarcoma (KS) is still one of the most common malignancies in patients with human
immunodeficiency virus (HIV) infection. Large randomized clinical trials have shown a …

Clinical characteristics of monkeypox virus infections among men with and without HIV: a large outbreak cohort in Germany

C Hoffmann, H Jessen, C Wyen, S Grunwald… - HIV …, 2023 - Wiley Online Library
Abstract Background Since May 2022, increasing numbers of monkeypox virus (MPXV)
infections have been reported from across Europe and North America. Studies, mainly from …

Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study

EM Berkowitz, G Moyle, HJ Stellbrink… - The Journal of …, 2015 - academic.oup.com
Background. Human immunodeficiency virus (HIV)–infected individuals are at increased risk
of herpes zoster (HZ), even in the antiretroviral therapy (ART) era. Because concerns exist …

[PDF][PDF] Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma

M Pashenkov, G Goëss, C Wagner… - Journal of Clinical …, 2006 - researchgate.net
Purpose The recent identification of toll-like receptors (TLRs) and respective ligands allows
the evaluation of novel dendritic cell (DC)–activating strategies. Stimulation of TLR9 directly …